Page 60 - IMO-2-3

Innovative Medicines & Omics Biocompatibility of nanomaterials

Table 2. Comparative biocompatibility metrics of selected
nanomaterials
Nanomaterial Hemolysis Complement Circulation Inflammatory
rate (%) activation half‑life response
(C3a level) (hours) (IL‑6/IL‑1β)
CaO–CaP 4.5 Moderate 6–8 Low (with
coating)
AuNPs 2.1 Low 12–24 Minimal
SiNPs 7.8 High 2–5 Elevated
PLGA 3.3 Low 8–12 Minimal
nanoparticles
LNPs 1.2 Very low 24+ Negligible
Abbreviations: AuNPs: Gold nanoparticles; CaO: Calcium oxide;
CaP: Calcium phosphate; IL: Interleukin; LNPs: Lipid nanoparticles; Figure 5. Synergistic strategies of scaffold architecture, signaling cues,
PLGA: Poly (lactic-co-glycolic acid); SiNPs: Silica nanoparticles.
and responsive biomaterials in bone tissue engineering. Image created by
the author.
components—design features that are challenging to Abbreviations: BMP: Bone morphogenetic protein; FDM: Fused
replicate using traditional scaffold manufacturing. As deposition modeling; SLA: Stereolithography; IL-6: Interleukin-6; VEGF:
shown in Figure 5, successful bone tissue engineering Vascular endothelial growth factor.
relies on synergistic integration of scaffold architecture,
signaling cues, and responsive biomaterials to drive effective in enhancing immune compatibility and targeted
effective regeneration. antiviral drug delivery, particularly for managing viral
infections. 19
The CaO–CaP binary system exemplifies the delicate
balance between biological reactivity and structural Addressing the challenges of scalability and
stability that defines successful nanomaterial applications reproducibility in nanomaterial production is critical for
in medicine. While its osteogenic potential and favorable clinical translation. To this end, spray-drying methods
integration are well-established, fine-tuning degradation have replaced traditional solvent evaporation techniques,
rates and immune compatibility remains crucial. As ongoing significantly improving nanoparticle uniformity and
51
innovations in surface coatings, biofunctionalization, and yield. Automated microfluidic platforms are also being
manufacturing techniques evolve, CaO–CaP composites developed to enable continuous nanoparticle synthesis
stand poised for greater clinical relevance, offering a with real-time process monitoring, minimizing batch-
tangible example of how theoretical biocompatibility to-batch variability. At S.T.E.L.L.A.R. Labs, we are
strategies can translate into real-world biomedical impact. currently integrating AI-guided microfluidic synthesis
and in-line spectroscopic monitoring to standardize
7. Emerging trends and future directions in particle morphology, size, and surface functionality—key
nanomedicine parameters for regulatory compliance and clinical-grade
manufacturing.
Nanomedicine is advancing rapidly, propelled by technological
convergence and multidisciplinary collaboration. Next- AI and machine learning are also transforming the
generation nanomaterials—such as quantum dots, carbon- design and validation of nanomaterials. AI-enabled
based structures, and multifunctional hybrid platforms—offer modeling allows rapid optimization of physicochemical
superior optical, electrical, and mechanical properties properties while predicting biocompatibility with high
while maintaining biocompatibility. These attributes make accuracy, thereby accelerating preclinical development and
them highly promising for precision drug delivery, targeted reducing experimental costs. 26,53
diagnostics, and image-guided therapy. 50,51 In parallel, the field of personalized medicine is evolving,
Clinical applications of nanotechnology are expanding with nanotechnology enabling tailored treatment strategies
across therapeutic domains. Multifunctional nanoplatforms based on individual genetic and physiological profiles.
have shown significant promise in managing colorectal A landmark application is the use of lipid nanoparticles
cancer, where they facilitate early detection, targeted (LNPs) in delivering mRNA vaccines, as seen during
drug delivery, and image-guided interventions, offering the COVID-19 pandemic. LNPs have proven effective in
a synergistic approach to both diagnosis and treatment. protecting and transporting nucleic acids to target cells
52
Likewise, surface-engineered nanomaterials have proven while minimizing systemic toxicity. This platform now

Volume 2 Issue 3 (2025) 54 doi: 10.36922/IMO025210024